Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL33 in pancreatic cancer-pro- or antitumor?

Trends in cancer - 1 May 2026

Sharma Supriya, Dixit Ajay

Abstract excerpt

Interleukin 33 (IL33) in the tumor microenvironment of pancreatic cancer has been linked to both pro- and antitumor immune responses, suggesting a context-dependent role. Herein, we discuss the current understanding and challenges of therapeutically targeting IL33 signaling in pancreatic cancer.

Topics

Join the communities discussing this publication.

Antineoplastic Agents, Immunological
Carcinoma, Pancreatic Ductal
Gene Expression Regulation, Neoplastic
Interleukin-1 Receptor-Like 1 Protein
Interleukin-33
Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pancreatic Neoplasms

Tumor Microenvironment

Source

Identifiers

PMID: 41813474
DOI: 10.1016/j.trecan.2026.01.009

Genes

IL33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL33 in pancreatic cancer-pro- or antitumor?PMID 41813474Read ↗

Pancreatic tumor initiation: the potential role of IL-33.Semantic proximity Read ↗

IL-33 biology in cancer: An update and future perspectivesSemantic proximity Read ↗

Interleukin-33: Friend or Foe in Gastrointestinal Tract Cancers?Semantic proximity Read ↗

Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic CancerSemantic proximity Read ↗

Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responsesSemantic proximity Read ↗

Exploiting inflammation for therapeutic gain in pancreatic cancer.Semantic proximity Read ↗

Inflammation and pancreatic cancer: disease promoter and new therapeutic target.Semantic proximity Read ↗

Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasisSemantic proximity Read ↗

Obesity-mediated upregulation of the YAP/IL33 signaling axis promotes an immunosuppressive tumor microenvironment in breast cancerSemantic proximity Read ↗

Exploring the role of interleukin 11 in cancer progression, patient survival, and therapeutic insightsSemantic proximity Read ↗

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasmsSemantic proximity Read ↗

Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.